LONDON, July 11, 2014 /PRNewswire/ --
On Thursday, July 10, 2014, the NASDAQ Composite ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the session at 16,915.07, down 0.42% and the S&P 500 closed at 1,964.68, down 0.41%. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.02% lower at 711.88, while the index has gained 9.23% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Nanosphere Inc. (NASDAQ: NSPH) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Free technical research on MDVN, IDIX, NSPH and PGNX can be downloaded upon signing up at:
Medivation Inc.'s stock edged 0.69% lower on Thursday, closing the session at $75.81. A total of 0.67 million shares were traded, which was below its three months average volume of 1.02 million shares. The stock moved between $74.69 and $76.27 during the session. Medivation Inc.'s stock has declined 0.11% in the previous three trading sessions and 1.06% in the last one month. However, the company's shares have gained 18.79% from the beginning of 2014. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $71.43 is above its 200-day moving average of $67.13. Furthermore, Medivation Inc.'s stock has a Relative Strength Index (RSI) of 55.28. Sign up today to read free research on MDVN at:
On Thursday, shares in Idenix Pharmaceuticals Inc. fluctuated between $23.99 and $24.10 before ending the session 0.41% lower at $24.00. On Thursday, the company's stock reported a trading volume of 1.70 million shares, below its three months average volume of 2.51 million shares. Over the last one month and on YTD basis, Idenix Pharmaceuticals Inc.'s stock has gained 1.44% and 301.34%, respectively, although, the company's stock is down 0.27% in the previous three trading sessions. Idenix Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $13.90 and $7.78, respectively. Further, the company's shares have an RSI of 90.92. Sign up today to read free research on IDIX at:
Nanosphere Inc.'s stock finished flat on Thursday, closing the day at the previous day's closing price of $1.52. The stock recorded a trading volume of 0.59 million shares, below its three months average volume of 1.12 million shares. The company's stock oscillated between $1.45 and $1.54 during the session. Shares in Nanosphere Inc. have gained 13.43% in the last one month. However, the company's shares have lost 0.65% in the previous three trading sessions and 33.62% since the start of this year. Nanosphere Inc.'s shares are trading above their 50-day moving average. The stock's 50-day moving average of $1.45 is below its 200-day moving average of $2.00. Moreover, the company's stock has an RSI of 51.55. Sign up today to read free research on NSPH at:
On Thursday, shares in Progenics Pharmaceuticals Inc. recorded a trading volume of 2.00 million shares, which was above its three months average volume of 1.23 million shares. On Thursday, the stock finished the day at $4.26, which was 0.47% lower its previous day's closing of $4.28, and registered an intraday range of $4.11 and $4.44. Shares in Progenics Pharmaceuticals Inc. have advanced 10.36% in the last one month, while the company's shares have fallen by 2.24% in the previous three trading sessions and 20.08% on YTD basis. Progenics Pharmaceuticals Inc.'s stock is trading above its 50-day moving average. The stock's 50-day moving average of $3.91 is below its 200-day moving average of $4.46. Additionally, the company's stock has an RSI of 52.62. Sign up today to read free research on PGNX at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.